Company
(location)

University/
nonprofit

Type of agreement

Product area

Details

Date

April

Abbvie Inc. (North Chicago)

University of Chicago

Five-year collaboration

Designed to improve the pace of discovery and advance medical research in oncology at both organizations

Their joint strategic research agreement will cover research in several areas of oncology, which could include, among others, breast, lung, prostate, colorectal and hematological cancers; Abbvie also gains an option for an exclusive license to certain University of Chicago discoveries made under the agreement and will provide funding for the collaboration that may be used for such activities as preclinical research, clinical trials and possible future programs at the university resulting from the partnership

4/21/16

ADC Therapeutics SA (Switzerland)

Cancer Research Technology and the University of Copenhagen

Licensing agreement

For antibodies against a cancer-specific cell surface protein

The antibodies will be used by ADCT to develop an antibody-drug conjugate (ADC) that could potentially treat a range of cancers

4/21/16

Aires Pharmaceuticals Inc. (subsidiary of Mast Therapeutics Inc.; San Diego)

Duke University

Agreement

To provide support for a randomized, double-blind, placebo-controlled phase II study testing AIR001 in patients with heart failure with preserved ejection fraction

The 100-patient study will test AIR001; terms were not disclosed

4/14/16

Altor Bioscience Corp. (Miramar, Fla.)

National Cancer Institute (NCI)

CRADA

To further develop ALT-803 and ALT-801

Terms were not disclosed

4/12/16

Antegrin Therapeutics Inc. (St. Louis)

Center for World Health & Medicine at St. Louis University

Licensing agreement

For a series of orally bioavailable antagonists of multiple pro-fibrotic integrins, intended to complement the company's portfolio of small-molecule candidates

Financial terms were not disclosed; Antegrin plans to select its first clinical candidate this year

4/7/16

Basilea Pharmaceutica Ltd. (Basel, Switzerland)

Biomedical Advanced Research and Development Authority

Contract

For the firm to conduct phase III development aiming at regulatory approval of broad-spectrum antibiotic ceftobiprole in the U.S.

In return, BARDA will provide funding of about $20M over an initial period of 18 months; BARDA may exercise further options, which would bring the total value of the contract up to $100M over a period of 4.5 years, upon successful completion of pre-defined milestones, including preclinical, clinical, manufacturing and associated regulatory activities

4/21/16

Bioasis Technologies Inc. (Vancouver, British Columbia)

Astellas Research Institute of America LLC

Collaboration

On the internalization and assessment of the Bioasis Transcend technology, Bioasis' brain delivery platform

The terms and targets were not disclosed

4/25/16

Chromadex Corp. (Irvine, Calif.) and Thorne Research

Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute

Research effort

For a planned study to assess the effect of nicotinamide riboside on brain NAD+ in college football players

The study will enroll healthy male collegiate football linemen, not having a history of more than three concussions; terms were not disclosed

4/14/16

Clinical Research Management Inc. (Hinckley, Ohio)

Biomedical Advanced Research and Development Authority

Collaboration

Under a six-month, $692,000 project funded by BARDA, Clinical Research will collect blood samples from people who have had confirmed Zika virus infection, in coordination with state and local health departments and the Centers for Disease Control and Prevention

Those samples will be collected and made available to diagnostic companies for use in validating the performance of their tests

4/29/16

Commense (Boston)

New York University

Exclusive, worldwide license agreement

For a key part of its microbiome platform, an approach focused on replenishing and bolstering the microbial exposure that a baby experiences at birth during passage

Research using the approach was published in the Feb. 1, 2016, issue of Nature Medicine

4/1/16

Cormorant Pharmaceuticals AB (Solna, Sweden)

Wistar Institute

Partnership

To analyze tumor biopsies with Cormorant's Humax-IL18 drug candidate, in phase I testing at the National Cancer Institute, using Wistar's methods

Scientists at Wistar have developed and validated a new biomarker that will show if a tumor is inhibiting the immune system's response to the tumor by targeting the migration of myeloid cells to tumor tissues; it will be used to determine the effects of Humax-IL-18 on tumor immunosuppression

4/28/16

Glaxosmithkline plc (London)

Sanford Burnham Prebys Medical Discovery Institute (La Jolla, Calif.)

Agreement

To investigate brain function with the aim of identifying and validating new therapeutic targets that can slow down or reverse neurodegeneration

The lab, located in La Jolla, Calif., is financially supported for three years with the possibility of an extension by GSK

4/21/16

Immunobiochem Corp. (Toronto)

Centre for the Commercialization of Antibodies and Biologics

N/A

Partnership to develop new therapeutics to treat breast cancer and other solid tumors

The agreement also grants Immunobiochem an option for the exclusive licensing of new intellectual property; CCAB is supporting the development of fully human antibodies against Immunobiochem's lead cancer target; the company will then engineer the antibodies into antibody-drug conjugates, complete preclinical development and take the molecules into the clinic

4/20/16

Jiangsu Hengrul Medicine Co. Ltd. (Lianyungang, China)

Albert Einstein College of Medicine

Agreement

Multiyear cancer research deal to develop innovative cancer therapies

The immediate goal is to discover new targets and develop therapies in oncology space

4/26/16

MRC Technology (London)

Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS; Shanghai)

Collaboration agreement

To develop new therapeutic antibodies from research originating in China

The Chinese Academy of Sciences is proposing to set up a new center to manage intellectual property and will also draw on MRC Technology's expertise in IP development, protection and management in this venture

4/11/16

Nantbioscience Inc. (Culver City, Calif.)

National Cancer Institute

CRADA

To further develop recombinant NK and monoclonal antibodies in monotherapy and in combination immunotherapies

Terms were not disclosed

4/6/16

Newlink Genetics Corp. (Ames, Iowa)

Defense Threat Reduction Agency of the U.S. Department of Defense

Contract

To support the development of vaccines against filovirus species, including Marburg and Ebola Sudan viruses, that could be combined with Ebola Zaire virus in a multivalent vaccine formulation or schedule

The $2.8M base contract has potential future options totaling $6.3M

4/18/16

Newlink Genetics Corp. (Ames, Iowa)

Biomedical Advanced Research and Development Authority

Option agreement

To support continued development of Newlink's rVSV-ZEBOV-GP (Ebola) vaccine candidate

The exercised option is worth $21.6M, which will be used to conduct clinical bridging studies

4/26/16

Nordic Nanovector ASA (Oslo, Norway)

Paul Scherrer Institute (Switzerland)

R&D collaborative agreement

To develop new antibody radionuclide conjugates to treat single cell leukemias, i.e., chronic lymphocytic leukemia and acute myeloid leukemia

Nordic was awarded NOK15M (US$1.83M) on Feb. 1 from the Research Council of Norway's user-driven research-based innovation

4/12/16

Oncternal Therapeutics Inc. (San Diego)

University of California, San Diego

N/A

Exclusive worldwide license to develop and commercialize antibodies and antibody-related binding agents recognizing receptor-tyrosine-like orphan receptor 1

The agreement also encompasses rights for all therapeutic indications to cimtuzumab, as well as rights to develop antibody-drug conjugates, genetically modified effector immune cells such as chimeric antigen receptor T cells, and bispecific antibodies; specific financial terms were not disclosed, but the deal includes up-front and milestone payments, research funding for the Kipps laboratory at UC San Diego, product royalties and an equity position in Oncternal

4/13/16

Pluristem Therapeutics Inc. (Haifa, Israel)

TES Holdings Co. Ltd. (venture company from the University of Tokyo)

Licensing agreement

To obtain a key patent (Patent No. 4554940) in Japan to cover the treatment of ischemic diseases with placental cell therapy

The patent covers use of all placenta-derived mesenchymal cells that are able to produce VEGF, a signaling protein that promotes the growth of new blood vessels

4/22/16

Protein Sciences Corp. (Meriden, Conn.) and Sinergium Biotech SA (Buenos Aires, Argentina)

Mundo Sano

N/A

Agreement to become members of a consortium to jointly develop a Zika virus vaccine to combat the recent outbreak in Latin America

Sinergium will pay an up-front fee to fund the development and manufacture of the vaccine being produced at Protein Sciences, in exchange for manufacturing and commercial rights to the vaccine in Argentina and other counties to be determined; the vaccine being developed is based on production of recombinant variations of the E protein from the Zika virus

4/20/16

Psioxus Therapeutics Ltd. (Oxford, U.K.)

Parker Institute for Cancer Immunotherapy

Memorandum of understanding

To develop and test armed oncolytic viral constructs using T-sign and Psioxus' manufacturing capabilities

The Institute is responsible for convening scientific and clinical thought leaders from its network to prioritize virus designs, including genetic payloads intended to prime or otherwise modify the tumor microenvironment for immune infiltration; Psioxus then plans to manufacture candidate viruses and make them available for human trials and other studies by researchers affiliated with the Institute

4/15/16

Regen Biopharma Inc. (San Diego)

Pan Am Cancer Treatment Center (Tijuana, Mexico)

License agreement

To test the company's experimental aplastic anemia treatment, Hemaxellerate, in a first-in-human proof-of-concept study

Up to 10 patients with chemotherapy-induced aplastic anemia will be treated with Hemaxellerate, and outcomes will be measured at one, three and six months; Hemaxellerate comprises cells extracted from the patient's own fat tissue and processed using a method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells

4/29/16

Sanofi SA (Paris)

Duke Clinical Research Institute and the Center for Assessment Technology and Continuous Health at Massachusetts General Hospital

Collaborations

Aimed at creating tools to help predict how type 2 diabetes patients adhere to their medications

Terms were not disclosed

4/28/16

Takeda Pharmaceuticals Co. Ltd. (Osaka, Japan)

University of Chicago and the Icahn School of Medicine at Mount Sinai in New York

Multiyear research partnership

For increased study in inflammatory bowel disease research and care

During the three-year partnership, the University of Chicago will work to establish a patient-physician digital platform that communicates real-time disease status, collates environmental, molecular, genetic and microbiome factors for each patient and creates a system for identifying personalized IBD therapy; Mount Sinai will focus on immunology in IBD, including discovering novel paradigms of lymphocytic homing to the colon, identifying the effect of the microbiome on homing to the colon and exploring therapeutic cell-based approaches to suppress intestinal inflammation

4/1/16

Txcell SA (Valbonne, France)

Ospedale San Raffaele

Strategic R&D collaboration

Includes a development arm focused on lupus nephritis, as well as a research program dedicated to CAR-Treg biology

Txcell and OSR will conduct the nonclinical pharmacology and toxicology studies with CAR-Treg cells to prepare for a first-in-man study in lupus nephritis

4/26/16

Viiv Healthcare Ltd.

The Medicines Patent Pool

Extended agreement

To increase access to dolutegravir to cover all remaining lower middle-income countries

The amendment to the 2014 license allows generic medicine distribution in four countries with patents – Armenia, Moldova, Morocco and Ukraine – that were not covered in the initial agreement

4/26/16

MAY

Arbutus Biopharma Corp. (Vancouver, British Columbia)

Saint Louis University Liver Center

Licensing and research collaboration

To develop ribonuclease H inhibitors, part of an effort to expand its pipeline by adding a program focused on a new aspect of the hepatitis B viral life cycle

RNaseH is a component of the viral polymerase and crucial to hepatitis B virus replication

5/5/16

Audentes Therapeutics Inc. (San Francisco)

Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania

Collaboration

To develop AT342, an AAV gene therapy for Crigler-Najjar syndrome

Terms were not disclosed

5/5/16

Bavarian Nordic A/S (Kvistgaard, Denmark)

U.S. government

Supply agreement

For its Imvamune smallpox vaccine

The second bulk supply order is part of a $100M deal on top of the $133M contract secured last year

5/20/16

Biogen Inc. (Cambridge, Mass.)

University of Pennsylvania

Collaboration and alliance

To advance gene therapy and gene editing technologies, focusing on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system and validating next-generation gene transfer technology using adeno-associated virus (AAV) gene delivery vectors

The university may receive up to $2B in research funding, options and milestone payments; Biogen will make an up-front payment of $20M with an additional $62.5M committed to fund R&D costs extending over the next three to five years in seven preclinical research and development programs; each program may trigger milestones that range from $77.5M to $137.5M per product as well as royalties payable on net sales of products; Biogen also receives an option to license next generation AAV vectors for certain indications

5/17/16

Biolinerx Ltd. (Tel Aviv, Israel)

MaRS Innovation

Framework collaboration agreement

The company intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities

MaRS Innovation is the commercialization agent for 15 of Toronto's academic institutions; terms were not disclosed

5/17/16

Biotheryx Inc. (Chappaqua, N.Y.)

Yissum Research Development Co. (of the Hebrew University of Jerusalem)

Exclusive worldwide license agreement

For the development and commercialization of drug candidates for hematologic and solid malignancies

Yissum's contribution involves research showing that inhibition of the clinically validated enzyme CKI-alpha induces several tumor suppressor pathways, including a new type of DNA damage response and p53 activation; Biotheryx and Yissum will focus on selecting and advancing clinical candidates designed to inhibit CKI-alpha

5/5/16

Boehringer Ingelheim GmbH (Ingelheim, Germany)

Lead Discovery Center GmbH and Max Planck Innovation GmbH

Agreement

Providing Boehringer with the option to take exclusive rights to a new lead compound to treat schizophrenia to be discovered and developed at the LDC

Boehringer will take a seat on the project development team and will pay an undisclosed option fee; the company will allocate internal resources to the program; once the project has attained proof of concept in relevant in vivo models, Boehringer can exclusively license the lead at pre-defined terms for subsequent preclinical and clinical development

5/12/16

Chugai Pharmaceutical Co. Ltd. (Tokyo)

Osaka University Immunology Frontier Research Center (IFReC)

Comprehensive collaboration

For advanced research in immunology

Chugai will provide ¥1B (US$9.1M) per year for a period of 10 years in return for access to information on results relating to independent basic research projects at IFReC and the right of first refusal for joint research

5/20/16

Editas Medicine Inc. (Cambridge, Mass.)

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT)

Three-year agreement

To support the discovery and development of CRISPR/Cas9-based therapies for the treatment of cystic fibrosis (CF)

CFFT will pay up to $5M to Editas; the deal also provides Editas with access to CFFT's network of CF scientific advisors and clinical researchers; Editas will explore targeting both common mutations as well as mutations not addressed by conventional approaches

5/17/16

Epizyme Inc. (Cambridge, Mass.)

Lymphoma Study Association

Collaboration

To research the process of combining tazemetostat with R-CHOP for those with diffuse large B-cell lymphoma

The phase Ib/II trial will be jointly conducted with the Lymphoma Academic Research Organisation, part of LYSA; the trial is expected to begin enrollment midyear

5/10/16

Galmed Pharmaceuticals Ltd. (Tel Aviv, Israel)

Icahn School of Medicine at Mount Sinai

Agreement

For a single-blinded study of Aramchol with supplemental vitamin D in patients with vitamin D deficiency and non-alcoholic fatty liver disease and fibrosis

The phase IIa trial will enroll 80 patients with NAFLD and fibrosis and is expected to be completed in the first half of 2018; the primary endpoint is the change in liver stiffness (baseline to end of treatment), as measured by magnetic resonance elastography, while secondary endpoints include changes in the intrahepatic fat content and other metabolic parameters

5/4/16

Ionis Pharmaceuticals Inc. (Carlsbad, Calif.)

University of Texas MD Anderson Cancer Center

Alliance

To discover and develop cancer therapeutics

The partners will combine advances made with Ionis' antisense technology, which provides enhanced potency for effectively engaging targets in solid and liquid tumors, with MD Anderson's expertise to develop novel therapeutic strategies to treat patients with a variety of cancers

5/24/16

Ipsen SA (Paris)

Institute of Molecular and Cell Biology (IMCB; Singapore)

Research partnership

To study the intracellular trafficking of botulinum neurotoxins (BoNTs) within neurons

By combining Ipsen's knowledge of BoNT recombinant engineering and biology with IMCB's understanding of membrane and toxin trafficking and RNA interference screening, as well as in RNA interference screening, the collaboration aims to work on the key components of intracellular trafficking involved in the biological action of BoNTs

5/17/16

Jiangsu Hengrul Medicine Co. Ltd. (Lianyungang, China)

University of Texas MD Anderson Cancer Center

Three-year agreement

For translational research to develop rational combination therapies and personalized medicines as well as to identify new treatment opportunities, especially in the field of immuno-oncology

Terms were not disclosed.

5/4/16

Juno Therapeutics Inc. (Seattle)

Seattle Children's Hospital

Letter of intent

To expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with glioma

The goal is to open phase I trials within the next two years

5/26/16

Morphosys AG (Martinsried, Germany)

University of Texas MD Anderson Cancer Center

Long-term strategic alliance

For the discovery and development of therapeutic antibodies against cancer

Morphosys will work with MD Anderson's Oncology Research for Biologics and Immunotherapy Translation, or ORBIT, unit, to apply its Ylanthia technology to generate and optimize fully human antibody candidates against jointly selected targets

5/25/16

Neurotrope Inc. (Newark, N.J.)

International Rett Syndrome Foundation

Research collaboration

To study the potential of bryostatin for the treatment of Rett syndrome

The purpose is to run a behavioral battery of tests to screen and assess the potential for bryostatin for the therapeutic treatment of Rett syndrome in a mouse model; all raw data, samples and specimens arising from the performance of that study will remain the property of Neurotrope, and the study will be funded and managed by the Rett group

5/20/16

Pharos Biologicals LLC (Baltimore)

Johns Hopkins University School of Medicine

Licensing agreement

For a patented lysosome-associated membrane protein, or LAMP, DNA vaccine technology and certain associated nanotechnologies to develop and deliver vaccines for influenza and flaviviruses

The company, formed in 2015 by J. Thomas August, a Johns Hopkins professor, is focusing initially on developing a Zika vaccine candidate followed by vaccines for dengue and influenza viruses

5/3/16

Sanofi Genzyme (global business unit of Sanofi SA; Paris)

Johns Hopkins School of Medicine

Research collaboration

To advance the understanding of underlying causes of disease progression in multiple sclerosis

Under the direction of a joint steering committee, the collaboration will leverage technologies and methodologies from both partners to inform new therapeutic approaches to treat disease progression; terms were not disclosed

5/17/16

Selecta Biosciences Inc. (Watertown, Mass.)

Massachusetts Eye and Ear

Exclusive license

Anc80 for use in a rare disease

Selecta also gained options for other pre-defined indications in the areas of lysosomal storage disorders, genetic muscular diseases and genetic metabolic diseases

5/20/16

Seres Therapeutics Inc. (Cambridge, Mass.)

Research Institute of St. Joseph's Hamilton and the Medical University of Graz

Research collaboration

To support its ongoing development of microbiome therapeutics for inflammatory bowel disease

Seres will collaborate with researchers; terms were not disclosed; Seres' pipeline includes SER-287, a biologically sourced candidate in a phase Ib study in patients with mild to moderate ulcerative colitis, and SER-301, a preclinical-stage candidate

5/5/16

Seres Therapeutics Inc. (Cambridge, Mass.)

Memorial Sloan Kettering Cancer Center

Strategic, multiyear research collaboration

To support the translation of discoveries from MSK laboratories into first-in-field microbiome therapeutics across multiple new cancer indications, where the microbiome may play a critical role

Seres and MSK have agreed to collaborate in two diverse areas of focus related to the discovery and development of microbiome therapeutics: improving the morbidity and mortality outcomes of patients undergoing hematopoietic stem cell transplantation for treatment of cancer, by prevention of transplant-related infections and graft-vs.-host disease; and increasing the efficacy and safety of checkpoint inhibitors used for immuno-oncology treatment. Both areas will be targeted using rationally designed consortia of microbiome bacteria

5/13/16

Seres Therapeutics Inc. (Cambridge, Mass.)

University of Pennsylvania

Multiyear collaboration

To support the development of treatment approaches for certain rare genetic metabolic diseases, including urea cycle disorders, and inflammatory bowel disease

The company disclosed financial terms for neither deal

5/13/16

Soligenix Inc. (Princeton, N.J.)

National Institute of Allergy and Infectious diseases

Exercised option

For Rivax bulk drug substance and finished drug product process scale-up and technology transfer that will support preclinical studies and manufacturing in accordance with current good manufacturing practices

The overall objectives of the contract are to advance the development of Soligenix's thermostabilization technology, Thermovax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure to prevent the effects of ricin exposure; the option will provide Soligenix with an additional $4.3M in funding

5/6/16

Takeda Pharmaceuticals Co. Ltd. (Osaka, Japan)

Bill & Melinda Gates Foundation

Partnership

To support polio eradication in developing countries

Funding from the $38M grant being used to develop, license and supply at least 50M doses per year of Sabin-strain inactivated poliovirus vaccine to more than 70 countries

5/10/16

The Cell and Gene Therapy Catapult (U.K.)

University of Aberdeen

Collaboration

To create Islexa Ltd., a new company developing a technology to produce laboratory grown islets, the organoids responsible for insulin production

Following successful results in initial preclinical studies of the technology, the company will initially continue to focus on further preclinical development of the protocol for reprogramming donated pancreatic tissue into functional islets; the company then hopes to take the technology into clinical trials in the next few years

5/19/16

Twoxar Inc. (Palo Alto, Calif.)

Department of Medicine at the University of Chicago

Collaboration

To identify and investigate potential new medicines to treat atherosclerosis

Twoxar will use its disease-to-candidate prediction software to integrate and analyze diverse biomedical data sets to predict efficacious drug candidates for in vivo testing, and university researchers will test the effectiveness of predicted drug candidates in promoting vascular endothelial health and in preventing atherosclerosis

5/26/16

U.S. Center for Innovation in Advanced Development and Manufacturing (led by Texas A&M University System

Biomedical Advanced Research and Development Authority

Collaboration

For an investigational second-generation anthrax vaccine, Nasoshield, under an 18-month, $10.5M task order from BARDA

The vaccine is being developed as a single-dose nose spray to protect against infections caused by inhaled anthrax and is designed to have an extended shelf life

5/11/16

JUNE

Agilis Biotherapeutics LLC (Cambridge, Mass.)

National Center for Accelerating Translational Sciences

CRADA

To facilitate development activities in support of registration of the company's gene-therapy candidate for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency

This gene therapy program was licensed from National Taiwan University, which treated 18 patients; following a single administration of the gene therapy, treated patients have shown substantial, durable gains in motor and cognitive function over multiple years, exhibited de novo production of dopamine as visualized by F-DOPA PET imaging, and realized improvements in metabolic biomarkers; the Agilis-TRND partnership will conduct toxicology, process development, and manufacturing work necessary for overall development of this therapeutic, and registration in the U.S. and abroad

6/28/16

Atox Bio Inc. (Ness Ziona, Israel)

Biomedical Advanced Research and Development Authority

Option agreement

To support the development of AB103 in patients with necrotizing soft tissue infections

The award brings BARDA's commitment to the company to $17.4M; the value of the increased contract in total is about $29M if all options are exercised

6/16/16

Bavarian Nordic A/S (Kvistgaard, Denmark)

Public Health Agency of Canada

Exercised option

For the supply of 171,000 doses of Imvamune smallpox vaccine to the national stockpile at a total value of $7.7M

The option builds upon an initial order of 189,000 doses, comprising a total of 360,000 doses ordered by the agency to date

6/16/16

Bellicum Pharmaceuticals Inc. (Houston)

Leiden University Medical Center (LUMC; the Netherlands)

Research agreement

To discover and validate natural high-affinity T-cell receptor (TCR) candidates targeting several cancers

The deal builds on an earlier agreement that gave Bellicum rights to TCR candidates targeting solid tumors that express PRAME (preferentially expressed antigen in melanoma) and other antigens; Bellicum will provide financial support to LUMC over a three-year term in exchange for the right to exclusively license any TCRs discovered during the collaboration

6/3/16

Bio-Path Holdings Inc. (Houston)

Thomas Jefferson University in Philadelphia

Collaborative agreement

To research Dnabilize, the company's antisense DNA technology, to develop an immunotherapy for brain cancer

The goal of the studies is to show that the technology is able to redirect patients' immune systems to fight cancer in their own bodies

6/29/16

Bone Biologics Corp. (Boston)

University of California, Los Angeles

Option agreement

For an opportunity to exclusively license the use of the bone growth factor Nell-1 in the treatment of osteoporosis

The company is already funding the development and formulation of a Nell-1 based product for use as a bone graft substitute focused on bone regeneration in spinal fusion procedures under an exclusive license from the school

6/15/16

Bristol-Myers Squibb Co. (New York)

Angola Sickle Cell Initiative (Houston)

Agreement

To provide medical treatment for children in Angola who suffer from sickle cell disease

The five-year cooperative endeavor will distribute Droxia (hydroxyurea) to those who need the medication; BMS will donate its product to treat up to 1,200 children in the first two years and will increase the number of participants to 4,100 after that period; the program will begin in Luanda and Cabinda and expand later to additional sites

6/28/16

Cantabio Pharmaceuticals Inc. (San Francisco)

Neuroscience Research Group at the University of Antioquia in Columbia

Collaboration

To further evaluate the company's DJ-1 protein-targeting small-molecule pharmaceutical chaperone drug candidates in development for the treatment of Parkinson's disease

The partnership brings together Cantabio's approach and the university's research expertise on the role of oxidative stress in PD and other neurodegenerative diseases

6/17/16

Cell Medica Ltd. (London)

Baylor College of Medicine

Partnership

To develop next-generation technologies for engineering immune cells with enhanced functions for the treatment of solid tumors

The collaboration provides Cell Medica with an exclusive license to several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor's research teams in the field of genetically engineered immune cells; under terms of the deal, Baylor will conduct preclinical and phase I research under the guidance of the project's joint steering committee

6/20/16

Cosmosid (Rockville, Md.)

Weill Cornell Medicine

Collaboration

On a global study to explore microbial community diversity, characterization of antimicrobial resistance genes and discovery of biosynthetic gene clusters from cities around the world

The study, an initiative of the Bill & Melinda Gates Foundation's Grand Challenges Explorations, will use Cosmosid's computational tools and curated genome databases to identify microbial community composition and AMR markers

6/22/16

Emergent Biosolutions Inc. (Gaithersburg, Md.)

Biomedical Advanced Research and Development Authority

Task order

To develop and manufacture three lots of a Zika vaccine to use in a phase I trial

The task order is valued at up to $21.9M; BARDA will provide a base vaccine candidate and Emergent will produce and conduct other processes required using current good manufacturing practice regulations

6/28/16

Enbiotix Inc. (Cambridge, Mass.)

Mayo Clinic

Agreement

To continue development of the firm's candidate, EPP-001, an engineered bacteriophage product to deliver biofilm-dispersing enzymes to treat Staphylococcus aureus infections in prosthetic joints

Enbiotix received a funding award from Mayo Clinic Ventures, which is helping to facilitate the project. Additional terms of the financing and collaboration agreement were undisclosed

6/14/16

Five Prime Therapeutics (South San Francisco)

University of Minnesota Medical School

Collaboration

To identify ways to generate hematopoietic stem cells capable of being transferred in vivo and regenerating the hematopoietic system

The research, funded by Regenerative Medicine Minnesota, will use Five Prime's library to screen more than 5,700 human extracellular proteins to identify those that promote the in vitro formation of human from inducible pluripotent stem cell line created by investigators

6/28/16

Immunovaccine Inc. (Halifax, Nova Scotia)

Leidos (U.S. defense company)

Subcontract

Covering the evaluation of its Depovax platform for use in developing peptide-based malaria vaccine targets

The subcontract is funded through Leidos' prime contract from the U.S. Agency for International Development. Leidos and Immunovaccine will collaborate to identify adjuvant and antigen combinations that can be used to protect against malaria and, with the Depovax delivery system, to formulate vaccine candidates for potential clinical testing

6/24/16

Immunovaccine Inc. (Halifax, Nova Scotia)

University of Edinburgh's Center for Immunity, Infection and Evolution (CIIE)

Preclinical collaboration

To explore whether CIIE-identified targets, when formulated in the Depovax delivery system, provide immunogenic responses against parasites that cause malaria

The collaborators expect to present data later this year

6/3/16

Immuron Ltd. (Melbourne, Australia)

Walter Reed Army Institute of Research

Collaboration

For the development of a vaccine for Shigellosis, also known as bacillary dysentery

The partners will investigate the anti-Shigella specific activity of antibodies contained in the current formulation of Travelan, its marketed product for the prevention of travelers' diarrhea, and assess their protective capacity in preclinical studies; in parallel, they will create a Shigella-specific bovine immunoglobulin product utilizing WRAIR antigens and Immuron's oral immunotherapy platform, testing the efficacy of the vaccines in vitro

6/24/16

Incyte Corp. (Wilmington, Del.)

Moffitt Cancer Center (Tampa, Fla.)

Collaboration

For Incyte to provide undisclosed funding to conduct three Moffitt blood cancer research programs over a three-year period

The programs will focus on specific cancers, including myeloproliferative neoplasms, mantle cell lymphoma, diffuse large B-cell lymphoma and chronic myelomonocytic leukemia, with the goal of improving the understanding of the basic cancer biology and interrogating certain therapeutic hypotheses involving Incyte's small-molecule therapeutics, both as single agents and in combination

6/2/16

Kite Pharma Inc. (Santa Monica, Calif.)

Experimental Transplantation and Immunology Branch of the National Cancer Institute

CRADA

For the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers

In a phase I/II study NCI will evaluate a TCR therapy candidate targeting HPV-16 E7 as a monotherapy and in combination with a checkpoint inhibitor in HPV-16 associated solid tumors; the NCI will also continue to advance a separately designed TCR therapy candidate targeting HPV-16 E6, currently in a phase I/II trial, under an existing CRADA between the company and the Surgery Branch of the NCI

6/21/16

Mannkind Corp. (Valencia, Calif.)

Juvenile Diabetes Research Foundation

Collaboration

To combine the group's scientific and human resources with Mannkind's diabetes research and development in order to advance new treatments and therapies

A focus of the collaboration will be on the use of the company's inhaled insulin Afrezza in the pediatric population

6/13/16

Merck KGaA (Darmstadt, Germany)

International Vaccine Institute (Seoul, South Korea)

Research agreement

To help develop more robust, scalable vaccine manufacturing processes

Merck will provide funding and expertise in the areas of clarification and purification

6/29/16

Nanoviricides Inc. (Shelton, Conn.)

St. Jude Children's Research Hospital

Agreement

For further development in its Flucide-I influenza program

The in vitro studies will evaluate the efficacy and potency of the company's nanoviricides antiviral agents against a panel of influenza A and B virus infection of different types of cells, including human bronchial epithelial cells

6/1/16

Sanofi SA (Paris)

Joslin Diabetes Center (Boston)

Collaboration

Extending their ongoing collaboration to explore targets for treatment of diabetes

The parties will direct joint efforts on research and development of new therapeutic options for the treatment of diabetic nephropathy, and explore implications of diabetes on cardiovascular disease

6/10/16

Seres Therapeutics Inc. (Cambridge, Mass.)

Mayo Clinic's Center for Individualized Medicine

Sponsored research agreement

Aiming to identify microbioime therapeutic candidates for liver diseases

Nicholas F. LaRusso, a professor with the Mayo Clinic, will conduct studies with Seres researchers to discover therapies for primary sclerosing cholangitis, or PSC, an orphan disease characterized by bile duct inflammation and reduction in bile acid flow

6/7/16

Seres Therapeutics Inc. (Cambridge, Mass.)

Massachusetts General Hospital of the Harvard Medical School

Collaboration

To identify microbiome therapeutics for obesity and metabolic syndrome. Seres will provide funding for a placebo-controlled, proof-of-concept study evaluating the impact of fecal microbiota transplantation derived from lean individuals on the body weight and glycemic control of adults with clinically significant obesity and metabolic disorders, including insulin resistance and metabolic syndrome

Seres will analyze patient samples to determine metagenomic signatures, metabolic markers and other clinical biomarkers to inform the design of microbiome therapeutics to treat the indications

6/23/16

Takeda Pharmaceuticals Co. Ltd. (Osaka, Japan)

Global Alliance for TB Drug Development

Agreement

To find new compounds to improve treatment of tuberculosis

The joint research program is funded through the Global Health Innovative Technology Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases

6/23/16

Tapimmune Inc. (Jacksonville, Fla.)

Mayo Clinic

Option agreement

Exercised worldwide license deal to a HER2neu vaccine technology

Tapimmune has the right to develop and commercialize the technology in any cancer indication in which the HER2neu antigen is overexpressed; the technology has completed phase I trials in HER2neu breast cancer patients, and a phase II trial is set to begin at the start of 2017

6/9/16

The Toulouse Cancer Santé Foundation (Toulouse, France)

Pierre Fabre Research Institute (Castres, France)

Research

To launch an immuno-oncology-focused research team within the Cancer Research Center of Toulouse

The team will receive five years of funding in equal parts of an undisclosed sum from the foundation and the institute

6/3/16

Txcell SA (Valbonne, France)

Lubeck Institute of Experimental Dermatology

R&D collaborative agreement

Covering the development of a CAR-Treg-based cellular immunotherapy for bullous pemphigoid

Txcell retains all rights to existing and future programs developed under the agreement

6/2/16

Txcell SA (Valbonne, France)

Yeda Research and Development Ltd. (tech transfer arm of the Weizmann Institute of Science; Rehovot, Israel)

Exclusive, worldwide licensing deal

For rights to develop and commercialize CAR-Treg products for autoimmune and inflammatory diseases

The European Patent Office recently granted a patent covering all redirected, genetically engineered Tregs, or CAR-Tregs, and their use in the suppression of autoimmune and inflammatory diseases

6/22/16

Yumanity Therapeutics Inc. (Cambridge, Mass.)

New York Stem Cell Foundation Research Institute

Discovery collaboration

To generate induced pluripotent stem cell lines for use in support of Yumanity's discovery efforts focused on new medicines for neurodegenerative diseases

Terms were not disclosed

6/23/16

Zymeworks Inc. (Vancouver, British Columbia)

University of Victoria and the BC Cancer Agency

Collaboration

To develop engineered cytokine and cytokine receptor pairs

The collaborators will engineer variant forms of cytokine-receptor complexes to allow precise control of cellular signaling events; engineered cytokine-receptor pairs will be designed using Zymeworks' Zymecad protein modeling and engineering technology, and further characterized at the University of Victoria and the BC Cancer Agency

6/27/16

JULY

Abcellera Biologics Inc. (Vancouver, British Columbia)

Massbiologics of the University of Massachusetts Medical School

Antibody discovery collaboration

That focuses on addressing the rapidly growing, unmet global health threat caused by the multidrug-resistant bacteria, Klebsiella pneumoniae

Abcellera will apply its single-cell antibody discovery platform to identify panels of antibody candidates against Klebsiella pneumoniae directly from human volunteers

7/21/16

Actinium Pharmaceuticals Inc. (New York)

Memorial Sloan Kettering Cancer Center

Agreement

To assign to provisional patent applications to Actinium

The company's deal with MSK, which already included issued patents that pertain to Actinium's Alpha Particle Immunotherapy technology platform and drug preparation methods, now includes those newly assigned provisional patent applications; those pertain to the labeling of monoclonal antibodies with Actinium-225 and the application of those Actinium-225-enabled antibodies for treating cancers

7/13/16

Aphios Corp. (Woburn, Mass.)

Frederick National Laboratory for Cancer Research

Subcontract

For the nanoformulation of a super hydrophobic cancer drug

The primary goal is to pair Brefeldin A (BFA), a cyclic macrolide with a lactone ring, with Aphios' Superfluids critical fluid nanosomes (SFS-CFN) technology for intravenous administration to achieve and maintain therapeutic plasma concentrations

7/13/16

Armagen Inc. (Calabasas, Calif.)

Rett Syndrome Research Trust

Collaboration

To develop a therapeutic for the treatment of Rett syndrome

Armagen will develop a form of the MeCP2 protein that can cross the blood-brain barrier in an effort to compensate for the mutated protein

7/6/16

Artes Biotechnology GmbH (Langenfeld, Germany)

Burnet Institute (Melbourne, Australia)

Agreement

To develop a vaccine to prevent transmission of hepatitis C virus

The vaccine will combine Burnet's Hepseevaxdelta3 technology with Artes' Metavax approach for the development of chimeric virus-like particle-based vaccines

7/27/16

Atriva Therapeutics GmbH (Tubingen, Germany)

University of Muenster, Germany

Acquisition

Of the co-infection patent that covers the beneficial use of MEK inhibitors against co-infections of bacteria, including multi-resistant bacterial strains such as MRSA

The company's product platform is based on a variety of different MEK kinase inhibitors focusing on severe viral infections and applicable for use with high-risk influenza patients

7/6/16

Aviragen Therapeutics Inc. (Alpharetta, Ga.)

Georgia State University's Institute for Biomedical Sciences

Agreement

To exclusively license, develop and commercialize respiratory syncytial virus replication inhibitors

Financial terms of the deal were not disclosed

7/6/16

Bioaffinity Technologies Inc. (San Antonio)

University of Texas Health Science Center at San Antonio

Renewed collaboration

To conduct R&D of cancer diagnostic and therapeutic agents using the company's porphyrin-based technology platform

Bioaffinity's wholly owned subsidiary, Oncoselect Therapeutics LLC, plans to exploit the company's porphyrin-based diagnostics to create targeted therapeutics to deliver chemotherapy drugs directly into cancer cells

7/14/16

Biocryst Pharmaceuticals Inc. (Research Triangle Park, N.C.)

National Institute of Allergy and Infectious diseases

Agreement

For efficacy studies of BCX4430 as a treatment for hemorrhagic fever viruses

Biocryst was awarded an additional $5.5M in funding; the studies will further assess effective dose regimens in nonhuman primates; to date, about $35.4 million of funding has been awarded under the contract

7/6/16

Bio-Path Holdings Inc. (Houston)

Thomas Jefferson University

Sponsored research agreement

To investigate the company's DNAbilize antisense DNA technology for the development of a brain cancer immunotherapy

A new sponsored research agreement struck between the parties builds on earlier work at the school, which evaluated the DNAbilize liposomal delivery and antisense technology in preclinical studies that the company said demonstrated efficacy, suggesting the potential for a systemic antisense immunotherapy for brain cancers

7/6/16

Boehringer Ingelheim GmbH (Ingelheim, Germany)

University of Dundee

Collaboration

With the aim of developing a new class of medicines targeting disease-causing proteins for degradation

The collaboration will combine the university's work on PROTACs, which are designed to harness the cell's natural disposal system (the ubiquitin-proteasome) to specifically remove disease-causing proteins, with Boehringer's expertise in discovery and clinical development

7/15/16

Cantabio Pharmaceuticals Inc. (San Francisco)

Purdue Research Foundation at Purdue University

Agreement

To advance the firm's development work on targeting DJ-1 protein small-molecule chaperone drug candidates for the treatment of Parkinson's disease and other related neurodegenerative diseases

The agreement gives Cantabio access to intellectual property derived from the joint research done at Purdue University and Cantabio

7/12/16

Editas Medicine Inc. (Cambridge, Mass.)

Fondazione Telethon and Ospedale San Raffaele

Scientific collaboration

To research and develop genome edited hematopoietic stem cell and T-cell therapies

Terms were not disclosed

7/29/16

Evotec AG (Hamburg, Germany)

Broad Institute of MIT and Harvard University

Non-exclusive license agreement

For the use of CRISPR-Cas9 gene-editing technology

Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform

7/6/16

Evotec AG (Hamburg, Germany)

Antibiotic Research UK

Contract

To form a collaboration with ANTRUK to study and develop new methods of treating infections that are resistant to currently used antibiotics

The collaboration will focus on finding antibiotic resistance breakers, or ARBs, to work in combination with known antibiotics in order to reverse resistance and restore clinical utility of those older antibiotics

7/12/16

F-star Biotechnology Ltd. (Cambridge, U.K.)

Christian Doppler Laboratory for Innovative Immunothera-peutics at BOKU, the University of Natural Resources and Life Sciences in Vienna

Multiyear collaboration

Extended collaboration to work on the design, development and biology of antibody and antibody-based therapeutics by harnessing the ability of the human immune system to attack diseased cells, such as cancer cells that usually remain undetected

The collaboration is jointly funded by the Austrian Federal Ministry of Science, Research and Economy and the company

7/15/16

Galmed Pharmaceuticals Ltd. (Tel Aviv, Israel)

Yeda Research and Development Ltd. (tech transfer arm of the Weizmann Institute of Science; Rehovot, Israel)

Research and option agreement

Aimed at assessing the effects of the company's Aramchol on the human gut microbiome

Galmed has the right to enter exclusive negotiations with Yeda to complete a license agreement to commercialize a diagnostic and/or prognostic tool for Aramchol and/or a diagnostic and/or prognostic tool in the field of liver disease

7/1/16

Horizon Discovery Group plc (Cambridge, U.K.)

Wistar Institute

Exclusive license agreement

For 153 melanoma patient-derived xenograft models

Horizon said that its distribution of the collection will allow scientists worldwide to investigate the preclinical efficacy and safety of their drugs; it will offer the collection as ungrafted PDX suspensions or as the basis of in vivo efficacy studies, where clients provide test compounds and Horizon's team will demonstrate their effect on PDXs grown in mice

7/21/16

Kite Pharma Inc. (Santa Monica, Calif.)

University of California, Los Angeles

Agreement

On a worldwide licensing deal regarding technology to develop off-the-shelf allogeneic T-cell therapies utilizing renewable pluripotent stem cells

Kite has exclusive rights to that technology to develop and commercialize T-cell products in oncology; in addition, Kite has made a sponsored research agreement with UCLA to support ongoing preclinical research on the ATO platform

7/27/16

Kite Pharma Inc. (Santa Monica, Calif.)

National Institutes of Health

Exclusive, worldwide license

For intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies

Terms were not disclosed

7/29/16

Merck & Co. Inc. (Kenilworth, N.J.)

Singapore's Agency for Science, Technology and Research

Two-year collaboration

Aimed at improving cellular delivery of macrocyclic peptides, a class of molecules that can potentially access therapeutic strategies that have been refractory to traditional approaches

Financial terms were not disclosed

7/20/16

Mount Tam Biotechnologies Inc. (Novato, Calif.)

Buck Institute for Research on Aging

Amended license and collaboration agreement

To settle an outstanding debt that the company owed the institute

Mount Tam paid $51,706 in exchange for extinguishing $326,796 in obligations to the institute under the deal, settling all outstanding payments owed to Buck; the agreement also temporarily halts a research collaboration between the parties until Mt. Tam secures $2M in financing

7/21/16

Novartis AG (Basel, Switzerland)

The Michael J. Fox Foundation for Parkinson's Research, Van Andel Research Institute and The Cure Parkinson's Trust

Collaboration

On clinical development of nilotinib, a tyrosine kinase inhibitor sold by Novartis

Nilotinib, or Tasigna for chronic myelogenous leukemia, will be developed for potential treatment in Parkinson's disease; the organizations aim to design and co-fund a therapeutic development program, including a double-blind, placebo-controlled trial of nilotinib, set to start in 2017

7/13/16

Onxeo SA (Paris)

Royal College of Surgeons in Ireland

Collaboration

For a discovery-stage program on the derivatives of Beleodaq (belinostat), an HDAC inhibitor

The program aims at optimizing the pharmacokinetic profile of belinostat, in order to increase its lifetime, its efficacy and its stability; research costs will be shared between Onxeo and RCSI; Onxeo will have an option to license RCSI's patents at negotiated rates; RCSI will lead compounds synthesis and in vitro testing, and Onxeo will lead the in vivo studies

7/8/16

Peregrine Pharmaceuticals Inc. (Tustin, Calif.)

University of Texas Southwestern Medical Center

Exclusive licensing deal

For an exosome technology that has potential application as a simple blood test to detect or monitor cancer

The company intends to develop a cancer test utilizing internal expertise and then pursue revenue-generating partnering opportunities at an early stage of development; the technology specifically relates to assays able to detect small amounts of phosphatidylserine (PS) exosomes

7/15/16

Redhill Biopharma Ltd. (Tel-Aviv, Israel)

U.S. National Institute of Allergy and Infectious Diseases

Research collaboration

To evaluate its experimental therapy to treat Ebola virus

The collaboration will evaluate survival outcome and assess disease severity by comparing viral loads and cytokine levels in active treatment arms and placebo; if successful, data from the study will be used to support discussions with the FDA for potential use of the animal rule pathway to seek approval

7/14/16

Sapience Therapeutics Inc. (Scarsdale, N.Y.)

Columbia University

Exclusive license agreement

For a transcription factor 5 inhibitor, for the potential treatment cancers, possibly including glioblastoma and neuroblastoma

Once administered, the candidate, called ST-36, prevents the activation of these genes in tumors, resulting in tumor-specific cell death

7/21/16

Sernova Corp. (London, Ontario)

JDRF

Research funding agreement

To help advance clinical trials of Sernova's CPS technologies for treatment of hypoglycemia unawareness patients with severe type 1 diabetes

Specifically, it will support a clinical trial at a major transplantation center in the U.S., with the goal to provide patients with hypoglycemia unawareness a cell therapy treatment utilizing Sernova's vascularized, cell macroencapsulated implantable and scalable device to reduce or eliminate the need for injections of exogenous insulin

7/13/16

Southern Research

The National Institute of Allergy and Infectious Diseases

Contract

For an initial $901,048, with a possibility of increasing the amount up to nearly $3.9M over the next two years, to expand research on the Zika virus

Funds will be used to develop a nonhuman primate model of Zika virus infections for product evaluation

7/18/16

Sprint Bioscience AB (Stockholm)

Center for Hematology and Regenerative Medicine at the Karolinska Institute

Agreement

Under which the parties will evaluate Sprint drug candidates to treat acute myeloid leukemia

The partnership intends to enable early stage identification of groups of patients who may benefit from a future drug; the work will be conducted at HERM´s and Sprint's respective research laboratories at Novum in Huddinge, Sweden

7/5/16

Therapix Biosciences Ltd. (Tel Aviv, Israel)

Yissum Research Development Co. (of the Hebrew University of Jerusalem)

Memorandum of understanding

To receive an exclusive, worldwide license to use a patent-protected formulation for nasal administration of cannabinoid substances

The technology is designed to facilitate administration and effective absorption of the active ingredient THC nasally

7/6/16

august

Abeona Therapeutics Inc. (Cleveland)

EB Research Partnership and EB Research Medical Foundation

Collaboration agreement

For gene therapy treatments for epidermolysis bullosa

Terms were not disclosed

8/10/16

Altimmune Inc. (Gaithersburg, Md.)

U.S. Biomedical Advanced Research and Development Authority

Contract

To fund the clinical development of Nasoshield, its anthrax vaccine candidate

Was awarded a contract valued at up to $120.2M over five years

8/2/16

Biolinerx Ltd. (Tel Aviv, Israel)

Hadasit, the Technology Transfer Company of Hadassah Medical Organization

Exclusive, worldwide agreement

To in-license a drug candidate to treat liver fibrosis and, in particular, nonalcoholic steatohepatitis

Terms were not disclosed; the candidate, BL-1210, designed to control liver fibrosis by modulating the immune system, is the first project to be in-licensed under a multi-year strategic collaboration between Biolinerx and Novartis AG, of Basel, Switzerland, initiated in December 2014

8/2/16

Biolinerx Ltd. (Tel Aviv, Israel)

University of Texas MD Anderson Cancer Center

Collaboration agreement

For a phase II study testing BL-8040 in combination with PD-1 inhibitor Keytruda (pembrolizumab, Merck & Co. Inc.) in pancreatic cancer

Biolinerx will supply BL-8040 for the study, which is expected to commence later this year

8/9/16

Cancer Research Technology (commercial arm of Cancer Research U.K.)

University of Birmingham and its commercial arm, Alta Innovations

Two-year collaboration agreement

Development and commercialization of the university's cancer research

The partners plan to share financial benefits derived from the work

8/9/16

Editas Medicine Inc. (Cambridge, Mass.)

Massachusetts General Hospital

Exclusive license agreement

To access intellectual property and technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the firm to address an expanded range of genetically defined diseases with potential for enhanced specificity

Financial terms were not disclosed

8/4/16

Emergent Biosolutions Inc. (Gaithersburg, Md.)

Centers for Disease Control

Contract option

For the supply of Vaccinia Immune globulin into the U.S. Strategic National Stockpile

The contract option is valued at $11.6M over 12 months; the therapeutic is licensed by the FDA to treat complications due to smallpox vaccination

8/11/16

Evelo Biosciences Inc. (Cambridge, Mass.)

Mayo Clinic

Exclusive collaboration

To advance immuno-microbiome-based therapies for cancer

The company will work with Mayo to isolate and characterize cancer-associated bacteria from patient stool samples and tumor biopsies in service of contributing to Evelo's cancer-associated bacteria library

8/3/16

Geovax Labs Inc. (Atlanta)

National Institute of Allergy and Infectious Diseases

Staged Vaccine Development contract

To further develop its preventive HIV vaccine (GOVX-B11) and to manufacture the DNA component of GOVX-B11 for use in advanced human trials

The base portion of the contract, with a value of $199,442, will support preparatory work for initiating manufacturing, and the contract also includes $7.6M in development options that may be exercised by NIAID, for a total potential contract value of $7.8M

8/3/16

Moleculin Biotech Inc. (Houston)

MD Anderson Cancer Center

Expanded sponsored research agreement

Also extended through August 2017

Terms were not disclosed

8/10/16

Vedanta Biosciences Inc. (Cambridge, Mass.)

NYU Langone Medical Center

Collaboration agreement

Focused on developing microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors

Vedanta will collaborate with a group of oncologists on clinical studies to support the identification of new microbiome immunotherapies

8/12/16

Vortex Biosciences Inc. (Menlo Park, Calif.)

Harvard University

Licensing agreement

For a series of four patents covering a cell electroporation technology

Vortex will combine that technology with its circulating tumor cell enrichment technology

8/4/16

Notes

This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

Some institutions listed have for-profit components.

CRADA = Cooperative Research and Development Agreement.

For more information about individual companies and/or products, see Thomson Reuters Cortellis.